carbamates has been researched along with End Stage Liver Disease in 7 studies
End Stage Liver Disease: Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From March 2016 to October 2016, 374 chronic hepatitis C patients were enrolled for this prospective, observational study and received SOF, DCV with ribavirin, to evaluate the changes in liver function parameters, international normalized ratio, complete blood count, model for end-stage liver disease, and Child-Turcotte-Pugh scores after achieving a sustained virological response 12 weeks after treatment." | 7.85 | Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. ( Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS, 2017) |
| " Treatment in the post-transplantation setting may be complicated by significant drug-drug interactions between antiviral agents and standard immune suppressive treatment regimens." | 5.48 | Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C. ( Dolman, GE; Gelson, WT; Selby, P, 2018) |
| "From March 2016 to October 2016, 374 chronic hepatitis C patients were enrolled for this prospective, observational study and received SOF, DCV with ribavirin, to evaluate the changes in liver function parameters, international normalized ratio, complete blood count, model for end-stage liver disease, and Child-Turcotte-Pugh scores after achieving a sustained virological response 12 weeks after treatment." | 3.85 | Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. ( Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS, 2017) |
| " Treatment in the post-transplantation setting may be complicated by significant drug-drug interactions between antiviral agents and standard immune suppressive treatment regimens." | 1.48 | Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C. ( Dolman, GE; Gelson, WT; Selby, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| El Kassas, M | 1 |
| Abdeen, N | 1 |
| Omran, D | 1 |
| Alboraie, M | 1 |
| Salaheldin, M | 1 |
| Eltabbakh, M | 1 |
| Farghaly, R | 1 |
| Emadeldeen, M | 1 |
| Afify, S | 1 |
| Sweedy, A | 1 |
| Ghalwash, A | 1 |
| Abbass, A | 1 |
| Ezzat, S | 1 |
| Tahoon, M | 1 |
| ELshazly, HM | 1 |
| Hamdy, H | 1 |
| Omar, H | 1 |
| Mohamed, MS | 1 |
| Hanafy, AS | 1 |
| Bassiony, MAA | 1 |
| Hussein, S | 1 |
| Dolman, GE | 1 |
| Selby, P | 1 |
| Gelson, WT | 1 |
| Kalafateli, M | 1 |
| Dusheiko, G | 1 |
| Manousou, P | 1 |
| Campos-Varela, I | 1 |
| Moreno, A | 1 |
| Morbey, A | 1 |
| Guaraldi, G | 1 |
| Hasson, H | 1 |
| Bhamidimarri, KR | 1 |
| Castells, L | 1 |
| Grewal, P | 1 |
| Baños, I | 1 |
| Bellot, P | 1 |
| Brainard, DM | 1 |
| McHutchison, JG | 1 |
| Terrault, NA | 1 |
| Herzer, K | 1 |
| Welzel, TM | 1 |
| Spengler, U | 1 |
| Hinrichsen, H | 1 |
| Klinker, H | 1 |
| Berg, T | 1 |
| Ferenci, P | 1 |
| Peck-Radosavljevic, M | 1 |
| Inderson, A | 1 |
| Zhao, Y | 1 |
| Jimenez-Exposito, MJ | 1 |
| Zeuzem, S | 1 |
| Castedal, M | 1 |
| Segenmark, M | 1 |
| Cederberg, S | 1 |
| Skoglund, C | 1 |
| Weiland, O | 1 |
7 other studies available for carbamates and End Stage Liver Disease
| Article | Year |
|---|---|
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fl | 2021 |
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; D | 2017 |
Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Dru | 2018 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepati | 2015 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease | 2016 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Live | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage L | 2017 |